The US regulatory review of Zealand Pharma A/S’s new drug for Type 2 diabetes, lixisenatide, is set to begin following the Food and Drug Administration’s acceptance of a registration file from the company’s partner, Sanofi SA. Lixisenatide is a GLP-1 receptor agonist.
